Holy Cross 9th Annual Winter Oncology Symposium
Avatar

Re-Challenging with Immunotherapy in Metastatic NSCLC: Would Retreatment with anti-PD-L1 Develop a Recurrent Side Effect?

By Holy Cross 9th Annual Winter Oncology Symposium FEATURING Ibiayi Dagogo-Jack
By Holy Cross 9th Annual Winter Oncology Symposium FEATURING Ibiayi Dagogo-Jack
316 views
May 15, 2019
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
18:47
Total Health

Updates in the Management of NSCLC: Systemic Therapy Year in Review

Feat. W. Iams
17:20
Total Health

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Feat. J. Porter
13:19
IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage

Duration of Immunotherapy Beyond 2 Years for Patients With Advanced …

Feat. E. Rodriguez
09:40
John Conibear

PACIFIC Trial 5-Year OS Data: Clinical Implications in NSCLC

07:31
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "KEYNOTE-671 Trial Key Learnings & Cli…

Feat. J. West
30:05
Cleveland Clinic Respiratory Institute

Diagnosis and Staging of Lung Cancer in the Era of Advanced Diagnost…

Feat. F. Almeida
17:34
ecancer

Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-…

Feat. L. Raez
20:27
Yale Cancer Center

Progress in the Treatment of NSCLC

Feat. R. Herbst
23:36
CHEST 2022 Coverage

Immune Checkpoint Inhibitor Pneumonitis in Lung Cancer

Feat. J. Possick
26:42
Total Health

ADAURA & KEYNOTE-671 Trials: Early Stage NSCLC Updates - 2023 AS…

Feat. J. Bauman
40:52
Houston Methodist Hospital

Respiratory Tract, EBUS, Molecular Biomarker Testing in Non-Small Ce…

Feat. S. Roy-Chowdhuri
08:15
ecancer

ESMO 2023 Summary: "Highlights From Recent NSCLC Trials"

Feat. B. Gyawali
23:29
2023 Evolution Conference

IO and Targeted Treatment for mNSCLC

Feat. M. Mooradian
03:44
ecancer

ASCO® 2023 Insights: "Dr. Wakelee on KEYNOTE-671 Study Updates …

Feat. H. Wakelee
07:38
GRACE

How Does PD-L1 Score Affect Treatment Options for NSCLC

Feat. S. Patel, T. Leal, P. Iyengar, A. Desai, C. Kim, J. Rotow
20:43
GRACE

Newer Types of Treatment for Lung Cancer: ADCs and Bispecifics

Feat. L. Bazhenova
04:31
Integrity Continuing Education

Neoadjuvant and Adjuvant Treatment in Early Stage NSCLC: Options Are…

Feat. J. Gainor, J. Sands
28:04
OncoAlert

Current Controversies in NSCLC Treatment

Feat. J. West
09:42
Robert Hsu

Unmet Need in NSCLC Treatment Options Following Progression on 1L IO…

20:28
OncoAlert

mNSCLC Updates: 1L EGFRm, 2/3L EGFRm & Anti-Trop2 ADC

Feat. C. Aggarwal